Rigel Pharmaceuticals, Inc. (RIGL) Posts Q2 Loss of 26c/Share
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Price: $48.67 +0.35%
Revenue Growth %: +15.2%
Financial Fact:
Contract revenues from collaborations: 3.76M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +15.2%
Financial Fact:
Contract revenues from collaborations: 3.76M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) reported Q2 EPS of ($0.26), $0.04 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $1.4 million versus the consensus estimate of $530 thousand.
For earnings history and earnings-related data on Rigel Pharmaceuticals, Inc. (RIGL) click here.
For earnings history and earnings-related data on Rigel Pharmaceuticals, Inc. (RIGL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- JPMorgan Starts Bytes Technology Group PLC (BYIT:LN) at Underweight
- JPMorgan Downgrades Woolworths Holdings Ltd (WHL:SJ) to Underweight
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
